What did TRUSCREEN GROUP LIMITED announce?
TRUSCREEN GROUP LIMITED (NZX: TRU) filed “Bangladesh Opportunity, Indian Subcontinent Expansion” with NZX on 8 November 2026, as an operational update announcement.
From the announcement:“TruScreen Group Limited (NZX/ASX: TRU) (“TruScreen” or “the Company”) is pleased to provide an update on its recent product presentation and training visit to Dhaka, Bangladesh, from 25 to 29 October 2026 as the Company expands across the Indian subcontinent.”
- Which company?
- TRUSCREEN GROUP LIMITED (NZX: TRU)
- When was it filed?
- 8 November 2026
- Where is the original?
- NZX announcement
Bangladesh Opportunity, Indian Subcontinent Expansion
NZX/ASX Announcement
9 November 2026
TruScreen Advances Bangladesh Opportunity to drive
Indian Subcontinent Expansion
Highlights
• TruScreen’s Dr Carolina Velasquez and Ms Sumaya Mozumder completed three days of product
presentation and training at the National Institute of Cancer Research & Hospital (NICRH) in Dhaka,
Bangladesh (26–28 October 2026), supporting local distributor Xerox Medica Ltd.
•
TruScreen presented its technology and connected screening results portal to key decision-makers
from the Bangladesh Ministry of Health and Family Welfare. Discussions focussed on supporting a
proposed national community screening model led by an all-female team of nurses and midwives.
•
The proposed program would support Bangladesh’s efforts to achieve the WHO’s cervical cancer
screening target of 70% by 2030.
•
Strategic visit, device demonstration and user training completed with digital healthcare provider
DocTime, opening a potential channel to reach women in the private health system.
•
Bangladesh is part of TruScreen’s co-ordinated Indian subcontinent strategy, together with India
(product registration expected) and Nepal (new distributor appointed ahead of a November
government tender).
TruScreen Group Limited (NZX/ASX: TRU) (“TruScreen” or “the Company”) is pleased to provide an
update on its recent product presentation and training visit to Dhaka, Bangladesh, from 25 to 29 October
2026 as the Company expands across the Indian subcontinent.
Ms Sumaya Mozumder, Business Development Manager for the Indian subcontinent, and Dr Carolina
Velasquez, Medical Affairs and Training Manager, were assisted by TruScreen’s Bangladesh distributor,
Xerox Medica Ltd (“Xerox Medica”) for the visit.
Cervical cancer in Bangladesh
Cervical cancer is the second most common cancer among women in Bangladesh, with an estimated
8,500 new cases and 5,000 deaths each year, the equivalent of around 14 women dying every day. ¹ More
than 64 million women aged 15 years and over are at risk, yet estimated screening coverage remains
below 10%. ¹
Bangladesh’s national screening program relies on visual inspection with acetic acid (VIA). Discussions
reinforced the key barriers to scaling VIA: limited trained personnel to screen every eligible woman; high
false-positive rates that require costly recall visits, with many women lost to follow-up; and cultural
reluctance among women to undergo invasive pelvic examination.
TruScreen’s non-invasive real-time, AI-enabled device will overcome these barriers. It delivers an
immediate result at point of care without laboratory infrastructure or specialist pathology and can be
conducted by trained nurses and midwives in community clinics. Women tested with an abnormal result
can be referred directly to a specialist.
Visit program
Ministry of Health and Family Welfare
Dr Velasquez presented TruScreen’s technology and clinical evidence to Dr Md. Nurul Islam and his
team from the Ministry of Health and Family Welfare at the Directorate General of Health Services
(DGHS). Discussions centred on deploying TruScreen in community clinics, and on TruScreen’s
connected screening results portal, which offers the Government access to population-level screening
data, including abnormal result rates by upazila (sub-district) and region.
National Institute of Cancer Research & Hospital
The TruScreen team also presented the product at NICRH in Mohakhali, Dhaka. NICRH is Bangladesh’s
national cancer institute and a leading referral centre. The session built awareness of TruScreen among
senior clinicians, and establishing key opinion leader support for TruScreen’s adoption.
DocTime Limited
TruScreen visited the headquarters of DocTime, a Bangladeshi digital healthcare provider, for a hands-
on device demonstration and knowledge-exchange session. DocTime’s mission of delivering digital
healthcare to women across Bangladesh offers a potential channel to extend cervical cancer screening
to the private health sector. Dr Velasquez provided device training for DocTime and Xerox Medica staff,
preparing the local teams for clinical demonstrations and anticipated sales activity.
Bangladesh visit, October 2026
Dr Carolina Velasquez and Ms Sumaya
Mozumder with the TruScreen device
Dr Velasquez presenting to Dr Md. Nurul
Islam and his team from the Ministry of
Health and Family Welfare
Visit to the Office of the Director, NICRH,
Dhaka
TruScreen and DocTime teams at
DocTime’s headquarters, Dhaka
Hands-on training with the TruScreen
device
Training participants with the TruScreen
team
Opportunities progressed
•
Government programs: Xerox Medica is in discussions with the Ministry of Health regarding cervical
cancer screening programs utilising TruScreen. The proposed projects would be funded by the
Bangladesh Government and development partners, including the World Bank and the Asian
Development Bank.
•
NGO funding: Xerox Medica is also progressing a grant application with the Shariatpur Development
Society, a national NGO, as previously reported in TruScreen’s newsletter, Beyond Screening.
•
Regulatory: Product registration for Bangladesh is pending to support volume procurement.
•
Awareness: Joint awareness initiatives targeting women through social media channels are being
developed with Xerox Medica.
Indian subcontinent expansion
Bangladesh is one of three priority markets in TruScreen’s Indian subcontinent strategy. Together, India,
Bangladesh and Nepal are home to more than 1.6 billion people, including 546 million women of
screening age.
India: Product registration is expected in December 2026, with distributor Renovate Biologicals
preparing for product launch in the world’s most populous country and fourth-largest economy.
TruScreen is also exploring collaborative opportunities with national NGOs, including PATH (Program for
Appropriate Technology in Health).
Nepal: Nova Biointermedicx Pvt Ltd is TruScreen’s distributor. Nova has extensive relationships across
Nepal’s central and provincial governments and elected to represent TruScreen after evaluating other
screening technologies. Nova will submit the TruScreen technology in a government tender opening in
November 2026. Nepal is working towards the WHO target of 70% screening coverage by 2030.
Commenting on the visit, Executive Chairman Tony Ho said:
“Bangladesh has one of the largest under-screened populations in the world, with a government looking
for scalable solutions to meet the WHO’s 70% screening target by 2030.
TruScreen’s portable, non-invasive AI-enabled real-time device allows nurses and midwives to screen
women in community clinics with an instant result in the same visit, while giving the Ministry of Health
the data it needs to manage a national program.
With India and Nepal progressing in parallel, the Indian subcontinent is shaping up as a significant growth
region for TruScreen.”
This announcement has been approved by the Board.
¹ ICO/IARC Information Centre on HPV and Cancer, Bangladesh Fact Sheet (March 2023), based on GLOBOCAN 2020 estimates; screening
coverage estimate 2019.
2
World Population Prospects, United Nations Population Division, World Bank
For more information, visit www.truscreen.com or contact:
TruScreen Group Limited
Tony Ho Guy Robertson
Executive Chairman Chief Financial Officer
tonyho@truscreen.com guyrobertson@truscreen.com
About TruScreen
TruScreen Group Limited (NZX/ASX: TRU) is a company listed in New Zealand and Australia with a real-
time, AI-enabled cervical cancer screening technology designed to detect pre-cancerous and cancerous
changes of the cervix. The TruScreen device is registered for use in multiple markets and has been used
to screen more than 1,200,000 women worldwide.
TruScreen’s technology is designed to support cervical cancer screening in settings where access to
laboratory infrastructure and specialist pathology services may be limited, making it well suited to
emerging markets and public screening initiatives.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.